NEWS

WIRES

OTHER

Research and Markets: Strong Pipeline to Alter the Course of Huntington's Disease in the Future - Pipeline Assessment and Market Forecasts to 2018

GlobalData, the industry analysis specialist, has released its new report, Huntington's Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Huntington's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Huntington's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Huntington's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global Huntington's Disease (HD) therapeutics market was valued at $246m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 13.4% over the next eight years to reach $676m by 2018. This high value growth is primarily attributed to high cost of therapy of Xenazine (tetrabenazine) in the US and Huntexil (pridopidine), which is expected to launch in 2014. Strong Pipeline to Alter the Course of Huntington's Disease in the Future

GlobalData's pipeline analysis revealed that there are 39 molecules in the pipeline in various stages of development. Majority of pipeline molecules are First-in-Class (FIC) with the mechanisms, aimed at delaying disease progression. The late-stage pipeline has four molecules such as HD-02 (creatine monohydrate), Huntexil, coenzyme Q10 and olanzapine. Of the four late-stage molecules, Huntexil and HD-02 have the potential to delay disease progression.

Key Topics Covered:

• List of Tables and Figures
• Huntington's Disease (HD) Therapeutics - Introduction
• Huntington's Disease Therapeutics - Market Characterization
• Huntington's Disease Therapeutics - Competitive Assessment
• Huntington's Disease Therapeutics - Pipeline Assessment
• Huntington's Disease Therapeutics - Clinical Trials Mapping
• Huntington's Disease Therapeutics - Strategic Assessment
• Huntington's Disease Therapeutics - Future Players
• Huntington's Disease Therapeutics - Licensing and Partnership Deals
• Huntington's Disease Therapeutics - Appendix

Companies Mentioned:

• Valeant Pharmaceuticals
• Avicena Group
• NeuroSearch A/S

For more information visit http://www.researchandmarkets.com/research/ad6487/huntingtons_disea

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716